Clinical Relevance of all-trans Retinoic Acid Pharmacokinetics and Its Modulation in Acute Promyelocytic Leukemia

References

• Lippman S. M., Kessler J. F., Meyskens F. L. Retinoids as preventive and therapeutic anticancer agents I. Cancer Treat. Rep. 1987; 71: 391–405
   PubMedGoogle Scholar
• Lippman S. M., Kessler J. F., Meyskens F. L. Retinoids as preventive and therapeutic anticancer agents II. Cancer Treat. Rep. 1987; 71: 493–515
   PubMedGoogle Scholar
• Pemrick S. M., Lucas D. A., Grippo J. F. The retinoid receptors. Leukemia 1994; 8: 1797–1806
   PubMed Web of Science ®Google Scholar
• Grignani F., Fagioli M., Alcalay M., Longo L., Pandolfi P. P., Donti E., Biondi A., Lo Coco F., Grignani F., Pelicci P. G. Acute promyelocytic leukemia: from genetics to treatment. Blood 1994; 83: 10–25
   PubMed Web of Science ®Google Scholar
• Alcalay M., Zangrilli D., Fagioli M., Pandolfi P. P., Mercarelli A., Lo Coco F., Biondi A., Grignani F., Pelicci P. G. Expression patterns of the Rar-alfa-PML function gene in acute promyelocytic leukemia. PNAS 1992; 89: 4840–46
   PubMed Web of Science ®Google Scholar
• Huang M. E., Ye Y. C., Chen S. R., Chai J. R., Lu J. X., Zhoa L., Gu L. J., Wang Z. Y. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567–572
   PubMed Web of Science ®Google Scholar
• Castaigne S., Chomienne C., Daniel M. T., Ballerini P., Berger R., Fenaux P., Degos L. All-trans retinoic acid as differentiation therapy for acute promyelocytic leukemia. Blood 1990; 76: 1704–1709
   PubMed Web of Science ®Google Scholar
• Warrell R. P., Frankel S. R., Miller W. H., Scheinberg D. A., Itri L. M., Hittelman W. N., Vyas R., Andreff M., Tafuri A., Jakubowski A., Gabrilove J., Gordon M. S., Dmitrovsky E. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans retinoic acid). N. Engl. J. Med. 1991; 324: 1385–1393
   PubMed Web of Science ®Google Scholar
• Chen Z. X., Xue Y. Q., Zhang R., Tao R. F., Xia X. M., Li C., Wang W., Zu W. Y., Yao X. Z., Ling B. J. A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. Blood 1991; 78: 1413–1419
   PubMed Web of Science ®Google Scholar
• Muindi J., Frankel S. R., Miller W. H., Jakubowsky A., Scheinberg D. A., Young C. W., Dmitrowsky E., Warrel R. P. Continuous treatment with all-trans retinoic acid results in a progressive decrease in plasma concentrations: implications for relapse and retinoid “resistance” in acute promyelocytic leukemia. Blood 1992; 79: 299–303
   PubMed Web of Science ®Google Scholar
• Warrell R. P. Retinoid resistance in acute promyelocytic leukemia: new mechanisms, strategies, and implications. Blood 1993; 82: 1949–1953
   PubMed Web of Science ®Google Scholar
• Tallman M. S. All-trans-retinoic acid in acute promyelocytic leukemia and its potential in other hematological malignancies. Sem. Hematol. 1994; 31, Suppl. 5, 38–48
   PubMed Web of Science ®Google Scholar
• Fenaux P. Results of APL 91 european trial combining ATRA and chemotherapy: presentation of APL 1993 trial. Leukemia 1994; 8, Suppl. 3, S70-S72
   Web of Science ®Google Scholar
• Lo Coco F., Diverio D., Avvisati G., Luciano A., Biondi A., Mandelli F. High frequency of early molecular remission in acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (Italian GIMEMA-AIEOP “AIDA” trial). Blood 1995; 86, No. 10, Suppl. 1, 265a
   PubMed Web of Science ®Google Scholar
• Brazzel R., Vane F., Ehmann C. Pharmacokinetics of isotretinoin during repetitive dosing to patients. J. Clin. Oncol. 1983; 11: 59–66
   Google Scholar
• Blaner W. S. Biochemistry and pharmacology of retinoids. Retinoids in Oncology, Hong Waun Ki, Lotan Reuben. Marcel Dekker, NY 1993; 1–42
   Google Scholar
• Fiorella P. D., Napoli J. L. Microsomal retinoic acid metabolism. J. Biol. Chem. 1994; 269: 10538–10544
   PubMed Web of Science ®Google Scholar
• Adamson P. C. Pharmacokinetics of all-trans-retinoic acid: clinical implications in acute promyelocytic leukemia. Seminars in Hematology 1994; 31, suppl. 5, 14–17
   PubMed Web of Science ®Google Scholar
• Adamson P. C. Clinical and pharmacokinetic studies of all-trans-retinoic acid in pediatric patients with cancer. Leukemia 1994; 8: 1813–1816
   PubMed Web of Science ®Google Scholar
• Muindi J. R., Frankel S. R., Huselton C., Degrazia F., Garland W. A., Young C. W., Warrel R. P. Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. Cancer Res. 1992; 52: 2138–2142
   PubMed Web of Science ®Google Scholar
• Muindi J. F., Young C. W. Lipid hydroperoxides greatly increase the rate of oxidative catabolism of all-trans retinoic acid by human cell culture microsomes genetically enriched in specified cytochrome P-450 isoforms. Cancer Res. 1993; 53: 1226–1229
   PubMed Web of Science ®Google Scholar
• Boylan J. F., Gudas L. J. Overexpression of the cellular retinoic acid binding protein-I (CRABP-I) results in a reduction in differentiation specific gene expression in F9 teratocarcinoma cells. J. Cell. Biol. 1991; 111: 965–970
   Web of Science ®Google Scholar
• Cornic M., Delva L., Guidez F., Balitrand N., Degos L., Chomienne C. Induction of retinoic acid-binding protein in normal and malignant human myeloid cells by retinoic acid in acute promyelocytic leukemia patients. Cancer Res. 1992; 52: 3329–3334
   PubMed Web of Science ®Google Scholar
• Adamson P. C., Boylan J. F., Balls F. M., Murphy R. F., Godwwin K. A., Gudas L. J., Poplack D. G. Time course of induction of metabolism of all-trans-retinoic acid and the up-regulation of cellular retinoic acid-binding protein (CRABP). Cancer Res. 1993; 53: 472–476
   PubMed Web of Science ®Google Scholar
• Estey E., Cabanillas F., Rosenblum M., Kurzrock R., Bole J., Andreeff M., Keating M., Kantarjian H., Lopez-Berenstein G. Phase I and pharmacology study of liposomal all-trans retinoic acid. Blood 1994; 84, Suppl. 1, 380a
   Web of Science ®Google Scholar
• Roberts A. B. Microsomal oxidation of retinoic acid in hamster liver, intestine and testis. Ann. N. Y. Acad. Sci. 1981; 359: 45–53
   PubMed Web of Science ®Google Scholar
• Bossche H. V., Willemsens G. Retinoic acid and cytochrome P-450. Retinoids: 10 years on, JH Saurat. Karger, Basel 1991; 79–88
   Google Scholar
• Van Wauwee J. P., Coene M. C., Goossens J., Cools W., Monbaliu J. Effects of cytocrhome P-450 inhibitors on the in vivo metabolism of all-trans retinoic-acid in rats. J. Pharmacol. Exp. Ther. 1990; 252: 365–369
   PubMed Web of Science ®Google Scholar
• Rigas J. R., Francis P. A., Muindi J. R. F., Kris M. G., Huselton C., Degrazia F., Orazem J. P., Young C. W., Warrell R. P. Constitutive variability in the pharmacokinetics of the natural retinoid, all-trans retinoic acid, and its modulation by keto-conazole. J. Natl. Cancer Inst. 1993; 85: 1921–1926
   PubMed Web of Science ®Google Scholar
• Lee J. S., Newman R. A., Lippman S. M., Fossella F. B., Calayag M., Raber M. N., Krakoff I. H., Hong W. K. Phase I evaluation of all-trans retinoic acid with and without ketoconazole in adults with solid tumors. J. Clin. Oncol. 1995; 13: 1501–1508
   PubMed Web of Science ®Google Scholar
• Castaigne S., Lefebvre P., Chomienne C., Suc E., Rigal-Huguet F., Gardin C., Delmer A., Archimbaud E., Tilly H., Janvier M., Isnard F., Travade P., Montfort L., Delannoy A., Rapp M. J., Christian B., Montastruc M., Weh H., Fenaux P., Dombret H., Gourmel B., Degos L. Effectiveness and pharmacokinetics of low-dose all-trans retinoic acid (25 mg/m2) in acute promyelocytic leukemia. Blood 1993; 82: 3560–3563
   PubMed Web of Science ®Google Scholar
• Bailey J., Pluda J. M., Foli A., Saville M. W., Bauza S., Adamson P. C., Murphy R. F., Cohen R. B., Broder S., Yarchoon R. Phase I/II study of intermittent all-trans-retinoic acid alone and in combination with interferon alfa-2a, in patients with epidemic Kaposi's sarcoma. J. Clin. Oncol. 1995; 13: 1966–1974
   PubMed Web of Science ®Google Scholar
• Adamson P. C., Bailey J., Pluda J., Poplack D. G., Bauza S., Murphy R. F., Yarchoan R., Balis F. M. Pharmacokinetics of all-trans-retinoic acid administered on an intermittent schedule. J. Clin. Oncol. 1995; 13: 1238–1240
   PubMed Web of Science ®Google Scholar
• Borden E. C. Interferons expanding therapeutic roles. N. Engl. J. Med. 1992; 226: 1491–1493
   Web of Science ®Google Scholar
• Hemmi H., Breitman T. Combinations of recombinant human interferons and retinoic acid synergistically induce differentiation of the human promyelocytic leukemia cell line HL-60. Blood. 1987; 69: 501–507
   PubMed Web of Science ®Google Scholar
• Bollag W. Retinoids and interferon: a new promising combination?. Br. J. Haematol. 1991; 79, Suppl. 1, 87–91
   PubMed Web of Science ®Google Scholar
• Lippman S. M., Glisson B. S., Kavanagh J. J., Lotan R., Hong W. K., Paredes-Espinoza M., Hittelman W. N., Holdener E. E., Krakoff I. H. Retinoic acid and interferon combination studies in human cancer. Eur. J. Cancer 1993; 29A: S9–S13
   PubMed Web of Science ®Google Scholar
• Moore D. M., Kalvakolanu D. V., Lippman S. M., Kavanagh J. J., Hong W. K., Borden E. C., Paredes-Espinoza M., Krakoff I. H. Retinoic acid and interferon in human cancer: mechanistic and clinical studies. Sem. Hematol. 1994; 31, Suppl. 5, 31–37
   PubMed Web of Science ®Google Scholar
• Okuno H., Kitao Y., Takasu M., Kano H., Kunieda K., Seki T., Shizaki Y., Sameshima Y. Depression of drug metabolizing activity in the human liver by interferon. a. Eur. J. Clin. Pharmacol. 1990; 39, 365–367
   Google Scholar
• Israel B. C., Blouin R. A., McIntyre W., Shedlofsky S. I. Effect of interferon α monotherapy on hepatic drug metabolism in cancer patients. Br. J. Clin. Pharmacol. 1993; 36: 229–235
   PubMed Web of Science ®Google Scholar
• Lazzarino M., Corso A., Regazzi M. B., Iacona I., Bernasconi C. Modulation of all-trans retinoid acid pharmacokinetics in acute promyelocytic leukemia by prolonged interferon-α therapy. Br. J. Haematol. 1995; 90: 928–930
   PubMed Web of Science ®Google Scholar
• Koller E., Krieger O., Kasparu H., Lutz D. Restoration of all-trans retinoic acid sensitivity by interferon in acute promyelocytic leukemia. Lancet. 1991; 338, 1154-1155 (Letter)
   Web of Science ®Google Scholar
• Warrell R. P. Retinoid resistance. Lancet. 1993; 341, 126 (Letter)
   PubMed Web of Science ®Google Scholar
• Dermime S., Grignani F., Monica C., Nervi C., Sozzi G., Talamo G. P., Marchesi E., Formelli F., Parmiani G., Pelicci P. G., Gambacorti-Passerini C. Occurrence of resistance to retinoic acid in the acute promyelocytic leukemia cell line NB4 is associated with altered expression of the PML/RARα protein. Blood 1993; 82: 1573–1577
   PubMed Web of Science ®Google Scholar
• Agadir A., Cornic M., Lefebvre P., Gourmel B., Balitrand N., Degos L., Chomienne C. Differential uptake of all-trans retinoic acid by acute promyelocytic leukemic cells: evidence for its role in retinoic acid efficacy. Leukemia 1995; 9: 139–145
   PubMed Web of Science ®Google Scholar